AIFA GMP-API Authorization
ADIENNE is very proud to announce that, on March 14th 2023, we have received from AIFA GMP-API the new Authorization to produce:
API from Biological Process
Authorization is referred to our IMP product monoclonal antibody for the treatment of acute graft-versus-host diseases (aGvHD). The new Authorizations will open new possibility to the therapies in a specific field as the treatment of aGvHD.


